Preclinical Evaluation of a Radiotheranostic Single-Domain Antibody Against Fibroblast Activation Protein α
Journal of Nuclear Medicine · 2023
DOI: 10.2967/jnumed.123.266381 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2023. Verfasst von Yana Dekempeneer und 10 weiteren Autor:innen. Beteiligte Einrichtung: Precirix NV/SA, Brussels, Belgium. Hauptthemen laut MEDLINE: Single-Domain Antibodies, Pancreatic Neoplasms. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Fibroblast activation protein α (FAP) is highly expressed on cancer-associated fibroblasts of epithelial-derived cancers. Breast, colon, and pancreatic tumors often show strong desmoplastic reactions, which result in a dominant presence of stromal cells. FAP has gained interest as a target for molecular imaging and targeted therapies. Single-domain antibodies (sdAbs) are the smallest antibody-derived fragments with beneficial pharmacokinetic properties for molecular imaging and targeted therapy.
Methods
We describe the generation, selection, and characterization of a sdAb against FAP. In mice, we assessed its imaging and therapeutic potential after radiolabeling with tracer-dose 131I and 68Ga for SPECT and PET imaging, respectively, and with 131I and 225Ac for targeted radionuclide therapy.
Results
The lead sdAb, 4AH29, exhibiting picomolar affinity for a distinct FAP epitope, recognized both purified and membrane-bound FAP protein. Radiolabeled versions, including [68Ga]Ga-DOTA-4AH29, [225Ac]Ac-DOTA-4AH29, and [131I]I-guanidinomethyl iodobenzoate (GMIB)-4AH29, displayed radiochemical purities exceeding 95% and effectively bound to recombinant human FAP protein and FAP-positive GM05389 human fibroblasts. These radiolabeled compounds exhibited rapid and specific accumulation in human FAP-positive U87-MG glioblastoma tumors, with low but specific uptake in lymph nodes, uterus, bone, and skin (∼2-3 percentage injected activity per gram of tissue [%IA/g]). Kidney clearance of unbound [131I]I-GMIB-4AH29 was fast (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Precirix NV/SA, Brussels, Belgium.
- Department of Medical Imaging, In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium.
- Department of Nuclear Medicine, UZ Brussel, Brussels, Belgium.
- Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium; and.
- Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium.
- Precirix NV/SA, Brussels, Belgium; matthias.dhuyvetter@precirix.com.
Zitieren
APA
Dekempeneer, Y., Massa, S., Santens, F., Navarro, L., Berdal, M., Lucero, M. M., Pombo Antunes, A. R., Lahoutte, T., Van Ginderachter, J. A., Devoogdt, N., & D'Huyvetter, M. (2023). Preclinical Evaluation of a Radiotheranostic Single-Domain Antibody Against Fibroblast Activation Protein α. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.266381
Vancouver
Dekempeneer Y, Massa S, Santens F, Navarro L, Berdal M, Lucero MM, et al. Preclinical Evaluation of a Radiotheranostic Single-Domain Antibody Against Fibroblast Activation Protein α. Journal of Nuclear Medicine. 2023. doi:10.2967/jnumed.123.266381
BibTeX
@article{Dekempeneer2023,
author = {Dekempeneer, Yana and Massa, Sam and Santens, Francis and Navarro, Laurent and Berdal, Marion and Lucero, Melissa Miranda and Pombo Antunes, Ana Rita and Lahoutte, Tony and Van Ginderachter, Jo A and Devoogdt, Nick and D'Huyvetter, Matthias},
title = {Preclinical Evaluation of a Radiotheranostic Single-Domain Antibody Against Fibroblast Activation Protein α},
journal = {Journal of Nuclear Medicine},
year = {2023},
doi = {10.2967/jnumed.123.266381}
}
EUVIMED